Editorial: What have we lost in the wake of the rosiglitazone controversy?

Endocr Pract. 2009 Apr;15(3):273-4. doi: 10.4158/EP.15.3.273.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Combinations
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Myocardial Infarction / chemically induced*
  • Myocardial Infarction / epidemiology
  • Risk Assessment
  • Risk Factors
  • Rosiglitazone
  • Thiazolidinediones / administration & dosage
  • Thiazolidinediones / adverse effects*
  • Thiazolidinediones / therapeutic use*
  • Treatment Outcome
  • Withholding Treatment / statistics & numerical data

Substances

  • Blood Glucose
  • Drug Combinations
  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone